Get the Stockscreener App
0.5461
1.66%
0.0089
Aspire Biopharma Holdings Inc stock is traded at $0.5461, with a volume of 4.13M.
It is up +1.66% in the last 24 hours and up +39.99% over the past month.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.
See More
Previous Close:
$0.5372
Open:
$0.506
24h Volume:
4.13M
Relative Volume:
0.20
Market Cap:
$27.05M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+52.12%
1M Performance:
+39.99%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.50
$0.5701
1-Week Range:
$0.43
$0.8753
52-Week Range:
$0.215
$2.10
Aspire Biopharma Holdings Inc Stock (ASBP) Company Profile
Name
Aspire Biopharma Holdings Inc
Sector
Industry
Phone
561-704-8527
Address
194 CANDELARO DRIVE, #233, HUMACAO
Compare ASBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ASBP
Aspire Biopharma Holdings Inc
|
0.5461 | 29.22M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Aspire Biopharma Holdings Inc Stock (ASBP) Latest News
Aspire Biopharma Holdings, Inc. Building a Base Near Support2025 Retail Activity & Weekly Setup with High ROI Potential - thegnnews.com
Aspire Biopharma Plummets 22.7%: E-Commerce Launch Volatility and Technical Divergence Spark Turbulence - AInvest
Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - BioSpace
Penny Stocks on the Move: Today’s Top Gainers and Biggest Decliners - AInvest
Aspire Shares Are Trading Higher Monday: What's Going On? - Benzinga
Crude Oil Moves Higher; US Homebuilder Sentiment Declines In August - Benzinga
Aspire Biopharma Holdings shares surge 67.69% intraday after positive clinical trial results for sublingual aspirin product. - AInvest
US Stocks Mixed; Riskified Shares Dip After Q2 Results - Benzinga
Breakthrough Heart Attack Treatment: Sublingual Aspirin Shows Superior Results in Aspire Biopharma Trial - Stock Titan
Aspire Biopharma names new executive chair - MSN
Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World - Lubbock Avalanche-Journal
Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20 - Miami Herald
Aspire Biopharma to Present at Sidoti Virtual Investor Conference - AInvest
Aspire Biopharma’s BUZZ BOMB Shows Promising Initial Feedback - MSN
Aspire Biopharma Holdings, Inc. SEC 10-Q Report - TradingView
New Pre-Workout BUZZ BOMB Hits Market With Instant-Acting Sublingual Technology - Stock Titan
Aspire Biopharma Holdings, Inc. Announces CEO Transition - Lubbock Avalanche-Journal
Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement - Petoskey News-Review
Riding the Waves: A Guide to Investing in ASBP Stock - investchronicle.com
Aspire Biopharma Holdings, Inc. shares rise 4.06% after-hours following Ultragenyx Pharmaceutical Inc. Q2 2025 earnings call. - AInvest
Aspire Biopharma Holdings, Inc. shares rise 2.10% after-hours after unveiling e-commerce platform and launching BUZZ BOMB supplement. - AInvest
What catalysts could drive Aspire Biopharma Holdings Inc. stock higher in 2025Expert Picks Tracker For Beginners - Jammu Links News
Game-Changing Pre-Workout Supplement Delivers Instant Energy Without Water MixingBUZZ BOMB Hits Market - Stock Titan
Why is Aspire Biopharma Holdings Inc. Equity Warrant stock attracting strong analyst attentionDaily Trading Insights With High Returns - Jammu Links News
Aspire Biopharma Announces Leadership Reshuffle Amid Resignations - msn.com
What makes Aspire Biopharma Holdings Inc. Equity Warrant stock price move sharplyPost Market Outlook For Smart Trading - Jammu Links News
Aspire Biopharma Leadership Shakeup: Chairman Takes CEO Role Amid Board Restructuring - Stock Titan
Aspire Biopharma CEO Out After Less Than Two Months, Two Directors Resign - 富途牛牛
ASBP CEO & Audit Chair Resign; Former CEO Returns as Interim | PWUPU SEC FilingForm 8-K - Stock Titan
Uncorrelated Capital Launches with $53M in Funding for Litigation Finance - The Arizona Republic
What catalysts could drive Aspire Biopharma Holdings Inc. Equity Warrant stock higher in 2025Capitalize on fast-moving stock trends - Jammu Links News
How many analysts rate Aspire Biopharma Holdings Inc. as a “Buy”Consistent triple returns - Jammu Links News
Why is Aspire Biopharma Holdings Inc. stock attracting strong analyst attentionSkyrocketing investment returns - Jammu Links News
What is the dividend policy of Aspire Biopharma Holdings Inc. stockConsistent triple-digit returns - Jammu Links News
How does Aspire Biopharma Holdings Inc. compare to its industry peersCapitalize on fast-growing stocks today - Jammu Links News
What is the risk reward ratio of investing in Aspire Biopharma Holdings Inc. stockUnlock powerful trading tools for investors - jammulinksnews.com
Is it the right time to buy Aspire Biopharma Holdings Inc. Equity Warrant stockCapitalize on emerging market trends - Jammu Links News
Aspire Biopharma Holdings Inc Stock (ASBP) Financials Data
There is no financial data for Aspire Biopharma Holdings Inc (ASBP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):